Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00340327
NCT00340327
Completed
Phase 1

An Ascending Single Dose Study of the Safety and Pharmacokinetics of IMA-638 Administered to Healthy Japanese Subjects

Wyeth is now a wholly owned subsidiary of Pfizer0 sitesJune 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealthy
DrugsIMA-638

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Healthy
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Primary Endpoint
Safety will be measured by evaluating physical examinations, vital signs, electrocardiograms (ECGs), and clinical laboratory test results.
Status
Completed
Last Updated
18 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the safety and drug levels for single, ascending doses of IMA-638 in healthy Japanese subjects.

Registry
clinicaltrials.gov
Start Date
June 2006
End Date
July 2007
Last Updated
18 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

  • •First generation healthy Japanese men and women of non-childbearing potential.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Safety will be measured by evaluating physical examinations, vital signs, electrocardiograms (ECGs), and clinical laboratory test results.

Secondary Outcomes

  • Drug levels and associated biomarkers will be evaluated.

Similar Trials

Completed
Phase 1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's DiseaseParkinson's Disease (PD)
NCT03033498AbbVie29
Completed
Phase 1
Study Evaluating The SBI-087 In Subjects With Systemic Lupus ErythematosusLupus Erythematosus, Systemic
NCT00714116Pfizer30
Completed
Phase 1
A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy VolunteersChemotherapy-induced Nausea and Vomiting
NCT02382666Tesaro, Inc.100
Completed
Phase 1
A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)Schizophrenia
NCT05953740Merck Sharp & Dohme LLC17
Completed
Phase 1
A Safety and Pharmacokinetics Study of ZB004 in Healthy ParticipantsHealthy Volunteers
NCT05794516Zenas BioPharma (USA), LLC40